As of 2024-12-12, the Relative Valuation of SAGE Therapeutics Inc (SAGE) is (152.32) USD. This relative valuation is based on P/E multiples. With the latest stock price at 5.89 USD, the upside of SAGE Therapeutics Inc based on Relative Valuation is -2686.1%.
The range of the Relative Valuation is (155.30) - (172.52) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 28.1x - 44.5x | 34.7x |
| Forward P/E multiples | 20.3x - 31.3x | 20.5x |
| Fair Price | (155.30) - (172.52) | (152.32) |
| Upside | -2736.7% - -3029.1% | -2686.1% |
| Date | P/E |
| 2024-11-29 | -0.99 |
| 2024-11-27 | -1.01 |
| 2024-11-26 | -1.04 |
| 2024-11-25 | -0.96 |
| 2024-11-22 | -0.94 |
| 2024-11-21 | -0.88 |
| 2024-11-20 | -0.89 |
| 2024-11-19 | -0.89 |
| 2024-11-18 | -0.87 |
| 2024-11-15 | -0.92 |
| 2024-11-14 | -0.97 |
| 2024-11-13 | -1.04 |
| 2024-11-12 | -1.04 |
| 2024-11-11 | -1.14 |
| 2024-11-08 | -1.14 |
| 2024-11-07 | -1.15 |
| 2024-11-06 | -1.08 |
| 2024-11-05 | -1.08 |
| 2024-11-04 | -1.05 |
| 2024-11-01 | -1.10 |
| 2024-10-31 | -1.10 |
| 2024-10-30 | -1.17 |
| 2024-10-29 | -1.54 |
| 2024-10-28 | -1.55 |
| 2024-10-25 | -1.45 |
| 2024-10-24 | -1.42 |
| 2024-10-23 | -1.39 |
| 2024-10-22 | -1.39 |
| 2024-10-21 | -1.41 |
| 2024-10-18 | -1.37 |
| 2024-10-17 | -1.31 |
| 2024-10-16 | -1.32 |
| 2024-10-15 | -1.24 |
| 2024-10-14 | -1.23 |
| 2024-10-11 | -1.19 |
| 2024-10-10 | -1.15 |
| 2024-10-09 | -1.18 |
| 2024-10-08 | -1.17 |
| 2024-10-07 | -1.22 |
| 2024-10-04 | -1.20 |
| 2024-10-03 | -1.27 |
| 2024-10-02 | -1.26 |
| 2024-10-01 | -1.26 |
| 2024-09-30 | -1.31 |
| 2024-09-27 | -1.32 |
| 2024-09-26 | -1.30 |
| 2024-09-25 | -1.27 |
| 2024-09-24 | -1.32 |
| 2024-09-23 | -1.31 |
| 2024-09-20 | -1.36 |